Claire BIOT was appointed Vice President, Life Sciences Industry, Dassault Systèmes in 2019.
Her multifaceted experience in healthcare-related research, business and government administration supports Dassault Systèmes aim to drive the life sciences industry’s digital transformation. As the industry shifts its focus to personalized medicine and patient-centric experiences, she is responsible for helping companies adopt a new unified approach to scientific innovation by using the 3DEXPERIENCE platform to catalyze the next generation of therapeutics.
Claire BIOT began her career as manager of industrial methods at the biopharmaceutical company LFB. Later, she was head of division, health products pricing and reimbursement at the French Ministry of Health. She was then appointed managing director of France’s Health products and Technologies Central Agency (AGEPS), a subsidiary of Greater Paris University Hospitals (AP-HP). Here, she oversaw 500 employees and two sites dedicated to the development of its procurement policy and supply chain, as well as the development and manufacturing of drugs for specific hospital unmet needs.
Claire BIOT graduated from France’s Ecole Polytechnique engineering institute. She later earned a Master of Science degree in life sciences from the Watson School of Biological Sciences in New York, and an engineering degree from the Corps des mines program in Paris. She studied cancer immunotherapy at Institut Pasteur in Paris and graduated with a doctorate in immunology.
Claire BIOT has been an active member of several World Health Organization working groups on health products, has co-authored four publications and was granted a patent in the field of immunotherapy. Additionally, Claire BIOT sits at Mauna Kea Technologies Board of Directors.
Mohammed CHERKAOUI is an award-winning professor, author, and internationally recognized researcher, and a pioneering figure in micromechanics, nuclear engineering, nuclear medicine, and drug discovery. Stanford University Report Ranks Vice President and Provost of Academic Affairs Dr. Mohammed CHERKAOUI Among the World’s Top 2% Scientists.
Dr. Mohammed CHERKAOUI has authored more than 200 publications including the first-ever micromechanics textbook. His international accolades include a tenured professorship at Georgia Institute of Technology, an Endowed Chair and professorship at Mississippi State University, the France Medal from the National Center for Scientific Research, the Obama Award under the Material Genome Initiative, and the Lorraine Award for Excellence in Technology Transfer.
Patrick JOHNSON is VP Corporate Science & Research at Dassault Systèmes. His mission is to define the scientific bases of the company’s solutions, invent new disruptive technologies for the Industry Renaissance and animate the group’s global research ecosystem.
After joining in 1996, Patrick held various positions in R&D, from Product Lifecycle Management infrastructure to virtual product design solutions for the CATIA flagship brand. In 2001, he became head of the artificial intelligence department and played an instrumental role with new engineering practices currently now adopted in multiple sectors, such as smart morphing templates, and industrial processes capitalization & reuse automation.
As Head of Corporate Research in 2004, he launched the development of original technologies for all brands, and significantly grew the global innovation ecosystem of public/private partnerships with prestigious research bodies. In addition, he launched a strategic diversification for 3DS, following a very large European research program (BioIntelligence), resulting in a suite of collaborative applications for the life sciences sector, and the creation of the BIOVIA brand with a worldwide R&D lab in modeling, simulation, big data for life sciences.
A graduate of ENSAE, Mr. JOHNSON is based at 3DS Headquarters near Paris. He is or has been a member of the National Academy of Technology as well as of the scientific boards of INRIA, and International Society of Computational Biology.
Ed is the Director for the Office of Science and Engineering Laboratories at the Center for Devices and Radiological Health, US FDA. The Office is responsible for providing technical expertise and analyses in support of the regulatory processes within CDRH. In addition, the c300 scientists and engineers engage in representing the Agency on International standards organizations, provide scientific guidance for policy, and "futureproof" the Center for technologies making their way into novel medical devices.
Previously, he was President and CEO of Ortho Regenerative Technologies, a biotech startup based in Montreal, developing novel biomaterial approaches to surgical soft tissue repair. During this appointment, Ed steered the company to listing on the Canadian stock exchange, and started the regulatory process for the technology with the Center for Biologics at FDA.
He has also held senior positions at Zimmer Biomet (Vice President of Biologics), where he was primarily responsible for the cartilage repair business, resulting in the division becoming Zimmer’s Business Unit of the Year for 2014, and other positions in both the pharmaceutical (Akela Pharma) and Orthopedics (Smith & Nephew) industries.